Asco Plc.

News & Analysis

asco plc. - All News and Analysis

• OSI Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript

  Seeking Alpha - 2009-07-22

  Question-and-Answer Session Operator (Operator instruction.) We’ll go first to Jeff Quinn with JP Morgan. Terry Bivens – JP Morgan Hi guys, this is Terry in for Jeff Today. Just a question – I’m wondering where are you – if you can, can you update us on where...

  Tags: OSI Pharmaceuticals Inc., Marketing, J.P. Morgan Chase & Co., Call Transcript, Asco Plc., Earnings, Morgan Stanley, Analysis, Accrual, Terry, Gabriel Leung Interim Analysis, Sales Strategy, Operational Accounting, Sales Force Management, Sales, Finance, Seeking Alpha

• Exelixis, Inc. Q1 2009 Earnings Call Transcript

  Seeking Alpha - 2009-05-07

  Question-and-Answer SessionOperator Operator instructions And your first question comes from the line of Edward Tenthoff of Piper Jaffray. Please proceed. Edward Tenthoff – Piper Jaffray Great, thank you very much. Just one quick clarification on Frank's comment on Boehringer upfront and congrats on that deal, guys. Will that be...

  Tags: Patient, U.S. Bancorp Piper Jaffray Inc., Call Transcript, Asco Plc., Earnings, Approval, Exelixis Inc., GBM, Seeking Alpha

• Tests Could Predict Benefit From Cancer Drugs

  - 2008-10-29

  What if a blood test or biopsy could predict if a cancer therapy will help cure you, or only make you feel worse? Tests like these, based on genes, proteins or other "molecular markers" may someday do just that for people battling colon, lung and pancreatic tumors, scientists reported at...

  Tags: Asco Plc., Kras d.d.

• ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO

  - 2008-06-03

  WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) announced today the presentation of encouraging clinical findings with trastuzumab-DM1 (T-DM1) at the 2008 American Society of Clinical Oncology ASCO Annual Meeting taking place in Chicago, IL. T-DM1 comprises ImmunoGen's DM1 cell-killing agent linked to Genentech's HER2-targeting antibody, trastuzumab. Genentech is developing T-DM1...

  Tags: Asco Plc., Genentech Inc., Company, ImmunoGen Inc.

• New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting

  - 2008-06-02

  MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the presentation of data from several satraplatin clinical trials at the 44th Annual Meeting of the American Society for Clinical Oncology ASCO in Chicago. "We are pleased that data from several satraplatin...

  Tags: Asco Plc., Company, GPC Biotech AG

• Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting

  - 2008-06-02

  MARTINSRIED/MUNICH, Germany & PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the presentation of the overall survival results from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial Satraplatin and Prednisone Against Refractory Cancer. The data were presented at the 44th Annual...

  Tags: Asco Plc., Company, GPC Biotech AG

• TransMolecular Reports Positive Results from Phase 1 Trial of Iodine-TM601 in Metastatic Melanoma

  - 2008-06-02

  - ASCO abstract re-confirms that intravenous radiolabeled TM601 can cross the blood-brain barrier and bind to tumor tissue- CAMBRIDGE, Mass. -- TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced positive interim Phase 1 data for its intravenous formulation of 131I-TM601 in metastatic melanoma in...

  Tags: Asco Plc., Company, TransMolecular Inc.

• Geron Presentations at the ASCO 2008 Annual Meeting

  - 2008-06-02

  New Data on Activity of GRN163L in T-cell Prolymphocytic Leukemia Cells MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today announced two presentations of its anti-cancer drug, GRN163L, given at the American Society of Clinical Oncology ASCO annual meeting in Chicago. Geron is currently testing GRN163L in four clinical...

  Tags: Asco Plc., Geron Corp.

• Gloucester Pharmaceuticals Announces Presentation of Romidepsin Phase 1 Data in Multiple Solid Tumors at ASCO

  - 2008-06-02

  Romidepsin/Gemcitabine Combination Warrants Further Exploration CAMBRIDGE, Mass. -- Gloucester Pharmaceuticals today announced results from a Phase 1 study of romidepsin in combination with gemcitabine in patients with solid tumors. The results from the Phase 1 study showed that the combination was generally well tolerated and indicated that further investigation...

  Tags: Asco Plc., Company

• Ipsen and Spirogen's SJG-136 Shows Encouraging Results in the Treatment of Refractory Solid Tumours At ASCO

  - 2008-06-02

  PARIS & LONDON -- Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN) and Spirogen Ltd. announced today that final results from a Phase I clinical trial of the DNA sequence recognizing minor groove binder SJG-136 sponsored by the US National Cancer Institute NCI under a Cooperative Research and Development Agreement CRADA...

  Tags: Asco Plc., Spirogen Ltd.